Guidelines for the welfare and use of animals in cancer research

被引：1136

作者：

Workman, P. ^{[1
]}

Aboagye, E. O. ^{[2
]}

Balkwill, F. ^{[3
]}

Balmain, A. ^{[4
]}

Bruder, G. ^{[5
]}

Chaplin, D. J. ^{[6
]}

Double, J. A. ^{[7
]}

Everitt, J. ^{[8
]}

Farningham, D. A. H. ^{[9
]}

Glennie, M. J. ^{[10
]}

Kelland, L. R. ^{[11
]}

Robinson, V. ^{[12
]}

Stratford, I. J. ^{[13
]}

Tozer, G. M. ^{[14
]}

Watson, S. ^{[15
]}

Wedge, S. R. ^{[16
]}

Eccles, S. A. ^{[1
]}

Navaratnam, V. ^{[17
]}

Ryder, S. ^{[17
]}

机构：

[1] Inst Canc Res, Canc Res UK Ctr Canc Therapeut, Sutton SM2 5NG, Surrey, England

[2] Univ London Imperial Coll Sci Technol & Med, Comprehens Canc Imaging Ctr, London W12 ONN, England

[3] John Vane Sci Ctr, Barts & London Sch Med & Dent, Ctr Canc & Inflammat, London EC1M 6BQ, England

[4] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94158 USA

[5] Univ Manchester, Paterson Inst Canc Res, Manchester M20 4BX, Lancs, England

[6] OXiGENE Inc, San Francisco, CA 94080 USA

[7] Univ Bradford, Bradford BD7 1DP, W Yorkshire, England

[8] GlaxoSmithkline Pharmaceut R&D, Res Triangle Pk, NC 27709 USA

[9] Imperial Canc Res Fund, Clare Hall Labs, S Mimms EN6 3LD, Herts, England

[10] Univ Southampton, Sch Med, Gen Hosp, Tenovus Lab,Canc Sci Div, Southampton SO16 6YD, Hants, England

[11] UCL, Wolfson Inst Biomed Res, Canc Res Technol Dev Labs, London WC1E 6BT, England

[12] Natl Ctr Replacement Refinement & Reduct Anim Res, London W1B 1AL, England

[13] Univ Manchester, Sch Pharm & Pharmaceut Sci, Manchester M13 9PT, Lancs, England

[14] Univ Sheffield, Sch Med, Dept Oncol, Sheffield S10 2RX, S Yorkshire, England

[15] Univ Hosp, Queens Med Ctr, Div Preclin Oncol & PRECOS, Nottingham NG7 2UH, England

[16] AstraZeneca, Canc Biosci, Macclesfield SK10 4TG, Cheshire, England

[17] ASPD, Home Off, London W1P 4DF, England

来源：

BRITISH JOURNAL OF CANCER | 2010年 / 102卷 / 11期

基金：

英国医学研究理事会;

关键词：

animal welfare; cancer research; fundamental and translational research; replacement; reduction and refinement (3Rs); pilot studies; tumour models; genetically engineered mouse models; human tumour xenografts; orthotopic models; metastatic models; therapy; imaging; pharmocokinetic; pharmacodynamic and efficacy studies; drugs; radiation therapy; imaging techniques; anaesthesia; restraint; humane endpoints; tumour burden; clinical signs; publication; best practice; ACUTE LYMPHOBLASTIC-LEUKEMIA; HUMAN GASTRIC-CANCER; MOUSE MODELS; BREAST-CANCER; TUMOR-GROWTH; COLON-CANCER; NUDE-MICE; IN-VITRO; INTRAVITAL MICROSCOPY; ANTITUMOR-ACTIVITY;

D O I：

10.1038/sj.bjc.6605642

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Animal experiments remain essential to understand the fundamental mechanisms underpinning malignancy and to discover improved methods to prevent, diagnose and treat cancer. Excellent standards of animal care are fully consistent with the conduct of high quality cancer research. Here we provide updated guidelines on the welfare and use of animals in cancer research. All experiments should incorporate the 3Rs: replacement, reduction and refinement. Focusing on animal welfare, we present recommendations on all aspects of cancer research, including: study design, statistics and pilot studies; choice of tumour models (e. g., genetically engineered, orthotopic and metastatic); therapy (including drugs and radiation); imaging (covering techniques, anaesthesia and restraint); humane endpoints (including tumour burden and site); and publication of best practice.

引用

页码：1555 / 1577

页数：23

共 219 条

[1]

Abatan OI, 2008, J AM ASSOC LAB ANIM, V47, P8

[2] Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma [J].

Aguirre, AJ ;

Bardeesy, N ;

Sinha, M ;

Lopez, L ;

Tuveson, DA ;

Horner, J ;

Redston, MS ;

DePinho, RA .

GENES & DEVELOPMENT, 2003, 17 (24) :3112-3126

[3] Ultraviolet B exposure activates Stat3 signaling via phosphorylation at tyrosine705 in skin of SKH1 hairless mouse:: A target for the management of skin cancer? [J].

Ahsan, H ;

Aziz, MH ;

Ahmad, N .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2005, 333 (01) :241-246

[4] Both soluble and membrane-bound forms of Flt3 ligand enhance tumor immunity following "suicide" gene therapy in a murine colon carcinoma model [J].

Alsheikhly, AR ;

Zweiri, J ;

Walmesley, AJ ;

Watson, AJM ;

Christmas, SE .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2004, 53 (11) :946-954

[5]

[Anonymous], 1988, BRIT J CANCER, V58, P109, DOI 10.1038/bjc.1988.174

[6] Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice [J].

Artandi, SE ;

Chang, S ;

Lee, SL ;

Alson, S ;

Gottlieb, GJ ;

Chin, L ;

DePinho, RA .

NATURE, 2000, 406 (6796) :641-645

[7] Caco-2 monolayers in experimental and theoretical predictions of drug transport (Reprinted from Advanced Drug Delivery Reviews, vol 22, pg 67-84, 1996) [J].

Artursson, P ;

Palm, K ;

Luthman, K .

ADVANCED DRUG DELIVERY REVIEWS, 2001, 46 (1-3) :27-43

[8] Good engraftment of B-cell precursor ALL in NOD-SCID mice [J].

Baersch, G ;

Mollers, T ;

Hotte, A ;

DockhornDworniczak, B ;

Rube, C ;

Ritter, J ;

Jurgens, H ;

Vormoor, J .

KLINISCHE PADIATRIE, 1997, 209 (04) :178-185

[9] Effects of N-acetylcysteine in an esophageal carcinogenesis model in rats treated with diethylnitrosamine and diethyldithiocarbamate [J].

Balansky, RM ;

Ganchev, G ;

D'Agostini, F ;

De Flora, S .

INTERNATIONAL JOURNAL OF CANCER, 2002, 98 (04) :493-497

[10] Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models [J].

Banerji, U ;

Walton, M ;

Raynaud, F ;

Grimshaw, R ;

Kelland, L ;

Valenti, M ;

Judson, I ;

Workman, P .

CLINICAL CANCER RESEARCH, 2005, 11 (19) :7023-7032

← 1 2 3 4 5 6 7 8 9 10 →